From a rebrand to clinical trial facilitation to the conference circuit, EmVenio covered a lot of ground. Here are some of the highlights of 2025.

The things achieved

EmVenio’s rebrand was a major accomplishment in 2025. Earlier this year, PCM Trials, EmVenio Research and Clinical Trial Service made the decision to align services under one brand, leading to the creation of who they are now: EmVenio Clinical Research. While their commitment to their mission and clients remains the same, their visual identity has undergone a refresh. From the colors to a new logo, the company’s new look and feel is authentically EmVenio – bright, warm, welcoming and, most importantly, people-centered.

EmVenio also launched Patient Navigator, a new service designed to eliminate logistical and financial barriers to clinical trial participation. Patient Navigator services include arranging transportation for patients and caregivers, securing lodging for patients for the duration of their study participation and assisting with financial reimbursement for eligible expenses. This is EmVenio’s way of rounding out the clinical trial experience, making it truly accessible to all patients of all backgrounds and life experiences.

The research supported

This year, EmVenio supported more than 140 clinical trials for sponsors and CROs. Among the highlights are two of the company’s principal investigators leading research at EmVenio’s dedicated sites:

  • Dr. Renee Dwaihy, M.D., based at EmVenio’s Garden City, Michigan research center, brings over a decade of experience in metabolic and obesity-related studies.
  • Dr. Deon Miller, D.O., located at EmVenio’s Riverdale, Georgia research center, is a board-certified emergency medicine physician with more than 10 years of clinical experience and six years as a principal investigator. She has led over 40 trials across diverse therapeutic areas, including obesity and metabolic health.

Additionally, the company expanded their PI team in 2025, adding new therapeutic areas such as adult and adolescent psychology and pain management. Collectively, EmVenio’s principal investigators average 14 years+ of clinical trial experience, and their combined expertise spans more than 100 therapeutic areas.

The places travelled

EmVenio’s team was out and about last year, attending conferences that took the team across the United States and Europe. In total, the company attended 26 conferences in three countries and seven states. They had a presence at conferences big and small, including DPHARM, SCRS US, SCRS EU, OCT SoCal, OCT New England, SCOPE EU, Clinical Trials in Rural & Triable Communities Pathways Symposium, CNS and DTRA – just to name a few. During their time on the circuit, the team participated in 12 speaker sessions, three speaker panels and hosted five networking receptions.

Additionally, EmVenio was honored to be named Best Clinical Research Company at this year’s Vaccine Industry Excellence Awards during the World Vaccine Congress. Every day, EmVenio works to make clinical trials more accessible and inclusive to create a more accurate reflection of real-world populations impacted by trial outcomes. This award was an especially meaningful recognition of years of hard work and dedication.

See you in 2026!

EmVenio covered a lot of ground in 2025 and are looking forward to continuing that upward trajectory in 2026. As the company continues to build out plans for the new year, its website will be updated. If you’ve met the team before or if this is your first time hearing of EmVenio, they’d love to connect and discuss how they can support your next clinical trial. Contact EmVenio today or schedule a meeting to get started.